Study: Avastin, docetaxel combo stalls breast cancer progression

02/12/2008 | NYTimes.com · TheStreet.com

A study involving 736 women found that the combination of Genentech's cancer drug Avastin and docetaxel chemotherapy extended progression-free survival in breast cancer patients who have not undergone chemotherapy. The new study, sponsored by Genentech shareholder Roche Holding, may shore up the drug's chances for FDA approval as a breast cancer drug.

View Full Article in:

NYTimes.com · TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC